Portland, OR, April 03, 2023 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global oral antiviral market generated $35.21 billion in 2021, and is estimated to reach $43.39 billion by 2031, witnessing a CAGR of 2.1% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscape, and competitive scenario. The report is a helpful source of information for leading market players, new entrants, investors, and stakeholders in devising strategies for the future and taking steps to strengthen their position in the market.
Request Sample PDF Brochure- https://www.alliedmarketresearch.com/request-sample/13038
Report coverage & details:
| Report Coverage | Details |
| Forecast Period | 2022–2031 |
| Base Year | 2021 |
| Market Size in 2021 | $35.21 Billion |
| Market Size in 2031 | $43.39 Billion |
| CAGR | 2.1% |
| No. of Pages in Report | 385 |
| Segments Covered | Indication, Drug Class, Distribution Channel and Region |
| Drivers | Increase in prevalence of antiviral infections |
| A rise in the number of product approvals for treating viral infections | |
| Increase in awareness about viral infection & treatment options available | |
| A rise in regulatory approvals for treating viral infections | |
| A rise in the adoption of strategies such as agreement and partnership by key players | |
| A rise in the prevalence of hepatitis cases | |
| Opportunities | Growth & innovations in the pharmaceutical industry for the manufacturing of oral antiviral drugs |
| Restraints | Stringent regulations regarding approval of oral antiviral drugs and side effects associated with it |
| Availability of generic versions of a drug due to expiry of patents of some oral antiviral drugs, which can reduce the market share of the original drug |
Impact of Covid-19 on Oral Antiviral Market:
- The COVID-19 pandemic positively affected the growth of the oral antiviral market, owing to a rise in the number of patients suffering from viral infections. The pandemic led to an increased number of outpatient medical visits, including preventive services, such as screening of patients for various viral diseases, such as HIV, influenza, and other viral infections.
- The pandemic led to a high demand for oral antiviral drugs as people looked for ways to protect themselves from the virus. This led to shortages of some oral antiviral drugs, leading to price hikes and difficulties in accessing the drugs.
- In addition, a rise in regulatory approvals and favorable policies for development of novel therapeutics to treat viral infections is likely to provide lucrative opportunity for the key market players.
Procure Complete Report (385 Pages PDF with Insights, Charts, Tables, and Figures) https://www.alliedmarketresearch.com/checkout-final/oral-antiviral-market
The report offers a detailed segmentation of the global oral antiviral market based on indication, drug class, distribution channel, and region. The report provides an analysis of each segment and sub-segment with the help of tables and figures. This analysis helps market players, investors, and new entrants in determining the sub-segments to be tapped on to achieve growth in the coming years.
Based on indication, the human immunodeficiency virus (HIV) segment held the largest share in 2021, accounting for more than three-fourths of the global oral antiviral market and would dominate the market in terms of revenue through 2031. The hepatitis segment, on the other hand, is estimated to witness the fastest CAGR of 2.6% during the forecast period. The report also discusses the influenza and others segments.
In terms of drug class, the reverse transcriptase inhibitors segment captured the largest market share of more than half of the global oral antiviral market in 2021 and is expected to dominate the market in terms of revenue through 2031. However, the others segment is likely to achieve the fastest CAGR of 2.4% through 2031.
In terms of distribution channel, the drug store and retail pharmacies segment captured the largest market share of nearly three-fifths of the global oral antiviral market in 2021 and is expected to lead the trail during the forecast period. However, the online providers segment is likely to achieve the fastest CAGR of 3.1% through 2031. The report also studies the protease inhibitors segment.
For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/13038
Based on region, the market in North America was the largest in 2021, accounting for over one-third of the global oral antiviral market in 2021 and is likely to maintain its dominance during the forecast period. However, the market in Asia-Pacific is expected to manifest the highest CAGR of 2.8% from 2022 to 2031. The other regions analyzed in the study include Europe and LAMEA.
Leading players of the global oral antiviral market analyzed in the research include F. Hoffman-La Roche Ltd, Merck & Co., Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Amneal Pharmaceuticals LLC, Viatris Inc., AbbVie Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., and Johnson & Johnson.
The report analyzes these key players of the global oral antiviral market. These players have adopted various strategies such as expansion, new product launches, partnerships, and others to increase their market penetration and strengthen their position in the industry. The report is helpful in determining the business performance, operating segments, product portfolio, and developments by every market player.
Trending Reports in Healthcare Industry-
Meniscus Repair System Market- Global Opportunity Analysis and Industry Forecast, 2021–2030
High Frequency Ventilators Market- Global Opportunity Analysis and Industry Forecast, 2021–2030
Motorized Prosthesis Market - Global Opportunity Analysis and Industry Forecast, 2021–2030
Local Anesthesia Drugs Market - Global Opportunity Analysis and Industry Forecast, 2021–2030
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model):
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Get access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
